Memory Studies

Re:Cognition Health is enrolling volunteers to participate in studies.

Current Studies

Cassava

The aim of this clinical trial is to evaluate the safety and efficacy of a novel oral drug candidate called simufilam in reducing the progression of mild-to-moderate Alzheimer’s disease when taken twice daily.

Clinical trials are scientific investigations in which individuals volunteer to aid in the discovery of answers to specific health-related inquiries. When conducted cautiously by medical professionals, clinical trials are the most secure and quickest means of discovering new therapies and methods to enhance health. To be eligible for this study, a potential participant must:

• Be ages 50 to 87 years old
• Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease
• Have a gradual change in memory for six months or more
• Have a family member or loved one who can be available as a study partner during the entire study
• Be fully vaccinated for COVID-19 or have had a previous COVID-19 infection

Prothena

This is a Multiple Ascending Dose Study to Evaluate the safety and tolerability of a drug called PRX012 in Subjects with Alzheimer’s Disease, when compared to a placebo. Joining our clinical trial is a valuable opportunity to contribute to the advancement of medical research while receiving compensation for your participation. Additionally, we may offer reimbursements for clinical trial-related travel expenses and do not require health insurance. Don’t miss out on the chance to make a meaningful impact on the future of healthcare. To be eligible for this study, a potential participant must:

• Be between the ages of 55 and 85
• Have a confirmed or suspected diagnosis of mild Alzheimer’s disease or mild cognitive impairment due to Alzheimer’s disease
• Have noticed gradual and progressive change in memory function for at least 6 months
• Be willing and able to complete brain imaging (MRI and PET scans)

CuraSen

Are you or a loved one grappling with mild cognitive impairment or mild dementia caused by Parkinson’s or Alzheimer’s disease? If the answer is yes, we are currently undertaking a clinical trial to assess the potential effectiveness of an experimental medication in treating these medical conditions. This is a placebo-Controlled study to Evaluate the Safety, Tolerability and Effects of CST-2032 and CST-107 on Cognition in Subjects with Mild Cognitive Impairment or Mild Dementia due to Parkinson’s or Alzheimer’s Disease. To be eligible for this study, a potential participant must:

• Be between the ages of 50 and 85
• Have a diagnosis of Mild Cognitive Impairment or Mild Dementia due to Parkinson’s or Alzheimer’s Disease.
• Have noticed a change in your memory
• Be willing to undergo routine blood tests, and receive cognitive and behavioral testing
• Have a caregiver or partner able to accompany at specified visits

SAGE – Lightwave Study

This is a placebo-controlled study to evaluate the effects of SAGE-718 in participants with Mild Cognitive Impairment or Mild Dementia due to Alzheimer’s Disease. The primary objective of the LIGHTWAVE study is to determine if the cognitive enhancements observed during the two-week LUMINARY dosing period will be sustained over a longer duration. The study will specifically evaluate the effectiveness of the drug using the Digit Symbol Substitution test, a brief cognitive assessment that is highly responsive to changes in cognition and is believed to provide the most accurate reflection of daily cognitive abilities in patients. To be eligible for this study, a potential participant must:

• Be between the ages of 50 and 80
• Have noticed a change in your memory
• Have a family member or loved one who can be available as a study partner during the study
• Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease – This is one of our more mild studies, so no diagnosis needed – as long as the patient has noticed significant concerns with their memory

Merck

A clinical trial is currently underway to evaluate the safety and efficacy of an experimental drug in individuals who have mild to moderate Alzheimer’s disease. The study involves testing various doses of the drug against a placebo (a capsule that looks identical but contains no active ingredients) to assess their effectiveness. To be eligible for this study, a potential participant must:

• Be between the ages of 55 to 90 years
• Have mild to moderate Alzheimer’s disease dementia
• Are currently taking cholinergic medication (such as Aricept, Razadyne, or Exelon),
• Have a trial partner or caregiver

Cognito

Be part of the development of a new device that has the potential to slow the progression of Alzheimer’s disease, from the comfort of home without medications or highly invasive procedures. The objective of this study is to assess the effect of gamma sensory stimulation in individuals with mild/moderate Alzheimer’s Disease on function, cognition and symptoms. To be eligible for this study, a potential participant must:

• Be between the ages of 50 and 85
• Have noticed a change in your memory
• Have a family member or loved one who can be available as a study partner during the study